Margaret Kellar
Psychiatric/Mental Health · Fairhope, ALNPI 1124644802
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 376 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 29.3% of the total. 2025 is the largest year on record at $1,667, 2.1 times the $806 reported in 2021.
Across 376 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$507
- Lundbeck LLC$499
- Takeda Pharmaceuticals U.S.A., Inc.$357
- Otsuka America Pharmaceutical, Inc.$340
- plus $2K from 15 others
What the payments were for
- Food & beverage$6,530100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 91 | $1,914 |
| AbbVie(2 entities) | 100 | $1,078 |
| Neurocrine Biosciences, Inc. | 18 | $507 |
| Lundbeck LLC | 32 | $499 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $357 |
| Otsuka America Pharmaceutical, Inc. | 21 | $340 |
| Corium, LLC | 22 | $322 |
| Alkermes, Inc. | 14 | $291 |
| Axsome Therapeutics, Inc. | 11 | $269 |
| Johnson & Johnson | 10 | $181 |
| Vanda Pharmaceuticals Inc. | 7 | $180 |
| Bausch Health US, LLC | 10 | $177 |
| Teva Pharmaceuticals USA, Inc. | 8 | $173 |
| Supernus Pharmaceuticals, Inc. | 3 | $87 |
| Eisai Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Indivior Inc. | 1 | $14 |
| Neos Therapeutics, LP | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
How this compares
$6,530 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $102,410 |
| VraylarCariprazine Hcl | 24 | $46,691 |
| TrintellixVortioxetine Hydrobromide | 14 | $13,795 |
| Aripiprazole | 125 | $6,664 |
| Quetiapine Fumarate | 175 | $3,151 |
| Atomoxetine Hcl | 17 | $3,096 |
| Duloxetine Hcl | 119 | $3,008 |
| Bupropion XlBupropion Hcl | 92 | $2,853 |
| Risperidone | 44 | $2,525 |
| Lamotrigine | 134 | $2,335 |
| Trazodone Hcl | 170 | $2,217 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 119 | $2,210 |
| Buspirone Hcl | 77 | $1,860 |
| Mirtazapine | 68 | $1,743 |
| Olanzapine | 47 | $1,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $507 | $102,41012 claims |
| AbbVieVraylar | $1,078 | $46,69124 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $357 | $13,79514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Fairhope
- Britni RabbeittFairhope$7K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
- John HayesMobile$30K
- Logan ThrasherHoover$22K
- Anthony PhillipsHelena$15K
- Ian KinzerHuntsville$15K
- Latisha AliHoover$15K
- Taylor BarrettGadsden$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.